Grufity logoGrufity logo
ScreenerStocksFundsSectorsWatchlists
PTCT

PTC Therapeutics Inc

PTCT

26.39USD+0.11 (+0.42%)Market Closed
Watchlist

Market Summary

USD26.39+0.11
Market Closed
0.42%

PTCT Alerts

  • Losses in recent quarter

PTCT Stock Price

View Fullscreen

PTCT RSI Chart

PTCT Valuation

Market Cap

2.0B

Price/Earnings (Trailing)

-3.1

Price/Sales (Trailing)

2.49

EV/EBITDA

-3.7

Price/Free Cashflow

-7.79

PTCT Price/Sales (Trailing)

PTCT Profitability

EBT Margin

-77.95%

Return on Equity

124.85%

Return on Assets

-35.51%

Free Cashflow Yield

-12.83%

PTCT Fundamentals

PTCT Revenue

Revenue (TTM)

798.2M

Revenue Y/Y

-9.46%

Revenue Q/Q

-8.06%

PTCT Earnings

Earnings (TTM)

-641.7M

Earnings Y/Y

-21.64%

Earnings Q/Q

33.14%

Price Action

Last 7 days

10%

Last 30 days

34.6%

Last 90 days

-35.6%

Trailing 12 Months

-31.1%

How does PTCT drawdown profile look like?

PTCT Financial Health

Current Ratio

1.39

PTCT Investor Care

Shares Dilution (1Y)

5.31%

Diluted EPS (TTM)

-8.65

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2023770.4M818.7M798.2M0
2022569.4M618.2M696.6M698.8M
2021430.4M471.9M492.2M538.6M
2020321.7M311.4M358.4M380.8M
2019261.8M278.5M296.4M307.0M
2018203.7M224.5M236.3M264.2M
201790.3M122.5M141.3M174.1M
201648.2M57.0M70.2M82.7M
201523.5M28.6M36.7M36.8M
201436.8M31.6M17.0M25.2M
201328.6M27.8M36.9M34.7M
2012113.1M115.9M36.7M33.9M
2011000105.4M

Latest Insider Trading transactions for PTCT

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Sep 06, 2023
young alethia
sold
-464,972
39.857
-11,666
-
Sep 06, 2023
young alethia
acquired
324,898
27.85
11,666
-
Jul 13, 2023
gravier pierre
acquired
-
-
26,000
chief financial officer
Jun 07, 2023
schmertzler michael
sold
-44,860
44.86
-1,000
-
Jun 06, 2023
bell william f. jr.
acquired
-
-
6,333
-
May 23, 2023
reeve emma
sold
-157,885
59.5342
-2,652
-
May 23, 2023
reeve emma
acquired
88,520
33.3786
2,652
-
May 22, 2023
reeve emma
acquired
237,484
33.3733
7,116
-
May 22, 2023
reeve emma
sold
-423,630
59.5321
-7,116
-
May 22, 2023
pauwels eric
sold
-118,791
59.0122
-2,013
chief business officer

1–10 of 50

Which funds bought or sold PTCT recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Dec 07, 2023
Hudson Bay Capital Management LP
new
-
1,344,600
1,344,600
-%
Dec 06, 2023
CITIGROUP INC
added
129
968,281
4,641,510
-%
Nov 30, 2023
Neo Ivy Capital Management
added
2,437
245,000
264,000
0.12%
Nov 24, 2023
DEUTSCHE BANK AG\
added
15.88
-474,185
837,708
-%
Nov 22, 2023
Graham Capital Management, L.P.
sold off
-100
-614,239
-
-%
Nov 21, 2023
Walleye Capital LLC
added
958
1,337,470
1,614,190
-%
Nov 21, 2023
COMERICA BANK
new
-
7,059
7,059
-%
Nov 17, 2023
JACOBS LEVY EQUITY MANAGEMENT, INC
added
10.21
-16,269,800
25,159,700
0.15%
Nov 17, 2023
Diversified Trust Co
added
2.45
-230,071
298,232
0.01%
Nov 17, 2023
TimesSquare Capital Management, LLC
sold off
-100
-23,278,000
-
-%

1–10 of 38

Latest Funds Activity

Are funds buying PTCT calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own PTCT
No. of Funds

Schedule 13G FIlings of PTC Therapeutics Inc

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Nov 13, 2023
fmr llc
-
0
SC 13G/A
Oct 30, 2023
camber capital management lp
5.31%
2,013
SC 13G
Feb 14, 2023
rtw investments, lp
7.7%
5,615,387
SC 13G/A
Feb 09, 2023
janus henderson group plc
2.8%
2,027,142
SC 13G/A
Feb 09, 2023
fmr llc
-
0
SC 13G/A
Feb 09, 2023
vanguard group inc
10.21%
7,339,520
SC 13G/A
Feb 06, 2023
wellington management group llp
10.34%
7,430,907
SC 13G/A
Feb 01, 2023
franklin resources inc
4.8%
3,489,687
SC 13G/A
Jan 24, 2023
blackrock inc.
9.2%
6,640,854
SC 13G/A
Jul 11, 2022
vanguard group inc
10.07%
7,183,692
SC 13G/A

Recent SEC filings of PTC Therapeutics Inc

View All Filings
Date Filed Form Type Document
Nov 13, 2023
SC 13G/A
Major Ownership Report
Nov 07, 2023
POSASR
POSASR
Oct 30, 2023
SC 13G
Major Ownership Report
Oct 26, 2023
8-K
Current Report
Oct 26, 2023
10-Q
Quarterly Report
Oct 19, 2023
8-K
Current Report
Oct 19, 2023
8-K
Current Report
Sep 28, 2023
8-K
Current Report
Sep 22, 2023
8-K
Current Report
Sep 15, 2023
8-K
Current Report

Peers (Alternatives to PTC Therapeutics Inc)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
31.5B
-
6.13% 411799.31%
-3.7K
218.4K
- -102.45%
30.6B
10.7B
12.59% -56.51%
-8.83
2.87
-53.67% -129.46%
21.3B
1.7B
0.38% -28.56%
-41.84
12.38
79.37% 56.87%
17.5B
2.3B
8.71% -10.95%
119.09
7.58
15.05% 75.21%
12.3B
3.6B
1.18% -34.97%
28.84
3.4
8.35% -51.49%
MID-CAP
7.4B
272.9M
33.62% 24.68%
-12.26
27.23
141.38% 4.43%
5.7B
-
10.65% 240.88%
-9.69
48.33
54.84% -12.96%
3.4B
631.9M
-9.53% 43.40%
-23.12
5.44
23.54% 31.53%
3.3B
223.4M
14.00% -9.85%
-16.45
14.86
- -26.24%
2.6B
240.7M
-11.63% -24.14%
-12.52
10.67
-1.03% -16.59%
SMALL-CAP
1.5B
348.4M
12.92% -15.71%
24.33
4.33
81.69% -7.29%
661.3M
1.0B
-18.09% -67.84%
-1.2
0.63
-43.15% 58.48%
100.5M
6.4M
- -79.35%
-0.61
15.6
-44.11% 50.48%
37.6M
-
385.71% 119.35%
-0.58
-
- -29.23%
23.7M
-
40.31% 4064.72%
-0.5
-
- -13.74%

PTC Therapeutics Inc News

Latest updates
MarketBeat07 Dec 202302:37 pm38 hours ago
Marketscreener.com06 Dec 202302:13 pm2 days ago
Yahoo Finance05 Dec 202302:01 pm3 days ago
Defense World04 Dec 202304:42 am4 days ago
Defense World28 Nov 202310:42 am10 days ago
Defense World28 Nov 202306:45 am10 days ago
Stocks Register15 Nov 202308:00 am23 days ago
Seeking Alpha06 Nov 202308:00 am32 days ago
Yahoo Finance03 Nov 202307:00 am35 days ago
Seeking Alpha01 Nov 202307:00 am37 days ago
Yahoo Finance30 Oct 202307:00 am39 days ago
Yahoo Finance27 Oct 202307:00 am42 days ago
Greenwich Time26 Oct 202308:33 pm43 days ago
PR Newswire19 Oct 202307:00 am50 days ago
Markets Insider19 Oct 202307:00 am50 days ago

Financials for PTC Therapeutics Inc

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Revenue-8.1%196,576,000213,808,000220,382,000167,412,500217,127,000165,526,000148,735,000165,230,500138,743,000116,676,000117,942,000118,864,000118,404,00075,239,00068,259,00096,459,00071,416,00085,522,00053,583,00085,833,00053,591,000
Operating Expenses-25.7%314,740,000423,351,000337,997,000367,752,000285,314,000257,888,000235,257,000249,958,500231,819,000215,169,000216,090,000215,238,000173,535,000262,512,000161,250,000169,243,000131,891,000124,280,000122,723,000131,476,000101,821,000
  S&GA Expenses-8.6%80,886,00088,449,00086,914,00092,717,50080,118,00079,892,00073,271,00086,548,00069,252,00068,878,00061,095,00075,456,00057,840,00053,659,00058,209,00063,497,50049,284,00049,215,00040,544,00048,666,00038,368,000
  R&D Expenses-11.7%164,212,000185,874,000195,124,000188,693,500165,462,000157,263,000140,078,000149,844,000130,845,000125,482,000134,513,000118,013,00092,998,000176,525,00090,107,00081,831,00063,076,00059,979,00052,566,00053,646,50054,368,000
EBITDA Margin----0.56-0.63-0.60-0.71-0.75-0.83-0.76-0.62-0.84-0.92-0.99-1.20-0.73-0.65-----
Interest Expenses25.2%11,710,0009,354,00012,956,0005,784,0004,406,0002,143,0006,130,000-1,0004,407,000-5,182,000-4,516,000408,0004,878,000651,0003,931,000-3,111,000846,0003,089,000
Income Taxes12.9%-33,620,000-38,596,0003,969,000-18,804,000-17,893,0003,392,0004,835,0004,657,500-36,000488,000451,00012,634,00022,288,00084,000222,00010,644,000-344,000774,000576,000-993,500355,000
Earnings Before Taxes29.9%-166,590,000-237,479,000-134,990,000-189,693,000-127,208,000-148,695,000-121,891,000-138,607,500-133,660,000-117,882,000-128,191,000-61,720,000-47,404,000-181,343,000-112,465,000-67,033,000-60,341,000-41,015,000-71,537,000-49,323,000-50,614,000
EBT Margin----0.78-0.84-0.77-0.88-0.90-0.96-0.90-0.75-0.97-1.06-1.14-1.35-0.87-0.78-----
Net Income33.1%-132,970,000-198,883,000-138,959,000-170,889,000-109,315,000-152,087,000-126,726,000-143,265,000-133,624,000-118,370,000-128,642,000-74,354,000-69,692,000-181,427,000-112,687,000-77,677,000-59,997,000-41,789,000-72,113,000-48,330,000-50,969,000
Net Income Margin----0.74-0.80-0.76-0.90-0.92-0.97-0.92-0.83-1.05-1.15-1.23-1.39-0.91-0.82-----
Free Cashflow----39,761,000-174,585,000-43,427,000-63,942,000-106,716,000-77,566,000-57,034,000-39,119,000-105,826,000-70,718,00023,351,000-76,970,000-87,577,000-14,859,000-----
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Assets-5.8%1,2601,3381,6091,7061,5761,8041,8001,9382,0072,0592,1122,2082,1811,4771,5461,6241,6411,2921,2841,1191,029
  Current Assets-8.4%5405906136945176957749541,0111,0661,1221,2321,244605692779807475479321313
    Cash Equivalents-20.7%165208167280121174152197197185154216441166131296531136201169207
  Inventory11.7%36.0032.0027.0022.0015.0015.0015.0016.0016.0016.0016.0019.0019.0018.0019.0019.0017.0017.0016.0016.0014.00
  Net PPE3.5%85.0082.0079.0073.0067.0065.0059.0053.0046.0043.0037.0034.0028.0027.0026.0022.0018.0015.0015.0013.009.00
  Goodwill0%82.0082.0082.0082.0082.0082.0082.0082.0082.0082.0082.0082.0082.0082.0082.0082.0082.0082.0082.0082.00100
Liabilities0.7%1,9311,9172,0662,0531,8031,9861,8901,9371,9021,8621,8191,7261,6709041,0171,029978803771768643
  Current Liabilities3.3%492476442406420567477509465291251277254202218236184174143167115
    LT Debt, Current------150150150149----18.0020.0020.0020.0020.0017.0012.007.00
    LT Debt, Non Current0.1%573573572572283282282282282430430309303297295294293136138141144
Shareholder's Equity-15.8%-670-579--347-226-182-1.00105197293482511572529594664489513351386
  Retained Earnings-4.4%-3,127-2,994-2,795-2,656-2,486-2,376-2,224-2,097-1,954-1,821-1,702-1,628-1,554-1,484-1,303-1,190-1,112-1,052-1,011-938-890
  Additional Paid-In Capital1.3%2,4472,4172,3402,3052,2232,1842,1532,1242,0932,0642,0342,1722,1012,0671,8341,7951,7761,5401,5231,2881,275
Shares Outstanding0.2%75.0075.0074.0073.0072.0071.0071.0071.0071.0070.0070.0070.0068.0064.0062.0062.0058.0057.0056.0047.0045.00
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Quarterly)
(In Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Cashflow From Operations-2.8%-14.52-14.12-29.49-165-38.04-55.24-97.40-68.84-51.19-31.14-100-64.3727.00-74.81-81.55-10.21-15.50-30.52-42.41-15.143.00
  Share Based Compensation-8.3%27.0029.0029.0027.0029.0028.0027.0026.0026.0026.0026.0021.0017.0017.0015.0011.0010.0011.009.008.009.00
Cashflow From Investing-24.6%-29.60-23.75-28.9732.0013672.0049.0068.0065.0056.0030.00-208-394142-101-22930.00-38.17-150-24.60-24.11
Cashflow From Financing-81.8%3.0018.004.00303-1394.001.004.003.004.0010.0040.00643-32.9218.002.003823.002264.005.00

PTCT Income Statement

2023-09-30
Consolidated Statements of Operations - USD ($)
$ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Revenues:    
Revenue$ 196,576$ 217,127$ 630,766$ 531,389
Operating expenses:    
Cost of product sales, excluding amortization of acquired intangible assets9,49314,01136,36833,785
Amortization of intangible assets58,64931,023145,46180,790
Research and development164,212165,462545,210462,802
Selling, general and administrative80,88680,118256,249233,280
Change in the fair value of contingent consideration1,500(5,300)(125,000)(32,200)
Intangible asset impairment  217,800 
Total operating expenses314,740285,3141,076,088778,457
Loss from operations(118,164)(68,187)(445,322)(247,068)
Interest expense, net(28,160)(20,880)(84,905)(66,371)
Other expense, net(20,266)(38,141)(8,832)(84,355)
Loss before income tax benefit(166,590)(127,208)(539,059)(397,794)
Income tax benefit33,62017,89368,2479,666
Net loss attributable to common stockholders$ (132,970)$ (109,315)$ (470,812)$ (388,128)
Weighted-average shares outstanding:    
Basic75,377,99771,654,67174,618,61171,415,849
Diluted75,377,99771,654,67174,618,61171,415,849
Net loss per share-basic and diluted (in dollars per share)    
Basic$ (1.76)$ (1.53)$ (6.31)$ (5.43)
Diluted$ (1.76)$ (1.53)$ (6.31)$ (5.43)
Net product revenue    
Revenues:    
Revenue$ 144,038$ 134,186$ 506,187$ 407,720
Collaboration revenue    
Revenues:    
Revenue050,017650,024
Royalty revenue    
Revenues:    
Revenue50,17332,924117,85773,645
Manufacturing revenue    
Revenues:    
Revenue$ 2,365$ 0$ 6,716$ 0

PTCT Balance Sheet

2023-09-30
Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 165,157$ 279,834
Marketable securities129,653130,871
Trade and royalty receivables, net165,718155,614
Inventory, net35,75221,808
Prepaid expenses and other current assets44,082105,658
Total current assets540,362693,785
Fixed assets, net85,03172,590
Intangible assets, net423,342705,891
Goodwill82,34182,341
Operating lease ROU assets94,072102,430
Deposits and other assets34,73748,582
Total assets1,259,8851,705,619
Current liabilities:  
Accounts payable and accrued expenses370,731320,366
Deferred revenue1,2241,351
Operating lease liabilities- current11,7039,370
Finance lease liabilities- current2,6113,000
Liability for sale of future royalties - current105,84972,149
Total current liabilities492,118406,236
Long-term debt573,174571,722
Contingent consideration payable39,000164,000
Deferred tax liability51,927102,834
Operating lease liabilities- noncurrent99,682100,860
Finance lease liabilities- noncurrent17,18418,675
Liability for sale of future royalties- noncurrent657,469685,737
Other long-term liabilities1412,641
Total liabilities1,930,6952,052,705
Stockholders' deficit:  
Common stock, $0.001 par value. Authorized 250,000,000 shares; issued and outstanding 75,459,022 shares at September 30, 2023. Authorized 250,000,000 shares; issued and outstanding 73,104,692 shares at December 31, 20227572
Additional paid-in capital2,447,2922,305,020
Accumulated other comprehensive income9,6094,796
Accumulated deficit(3,127,786)(2,656,974)
Total stockholders' deficit(670,810)(347,086)
Total liabilities and stockholders' deficit$ 1,259,885$ 1,705,619
PTCT
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, such as rare diseases. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States, as well as to treat nonsense mutation Duchenne muscular dystrophy in Brazil and Russia; commercializes Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean; and markets Evrysdi for the treatment of spinal muscular atrophy in adults and children two months and older in Brazil. The company's splicing platform includes PTC518, which is being developed for the treatment of Huntington's disease; bio-e platform, such as vatiquinone and utreloxastat; metabolic platform comprising sepiapterin; gene therapy platform, including an asset targeting Friedreich ataxia; oncology platform, such as Unesbulin; and other multi-platform. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation to advance drug discovery and development research in regenerative medicine; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.
 CEO
 WEBSITEwww.ptcbio.com
 EMPLOYEES1402

PTC Therapeutics Inc Frequently Asked Questions


What is the ticker symbol for PTC Therapeutics Inc? What does PTCT stand for in stocks?

PTCT is the stock ticker symbol of PTC Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of PTC Therapeutics Inc (PTCT)?

As of Fri Dec 08 2023, market cap of PTC Therapeutics Inc is 1.99 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of PTCT stock?

You can check PTCT's fair value in chart. The fair value of PTC Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of PTC Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for PTCT so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is PTC Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether PTCT is over valued or under valued. Whether PTC Therapeutics Inc is cheap or expensive depends on the assumptions which impact PTC Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for PTCT.

What is PTC Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Dec 08 2023, PTCT's PE ratio (Price to Earnings) is -3.1 and Price to Sales (PS) ratio is 2.49. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. PTCT PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on PTC Therapeutics Inc's stock?

In the past 10 years, PTC Therapeutics Inc has provided 0.048 (multiply by 100 for percentage) rate of return.